Skipping doses could cut cancer drug costs without losing effect

NCT ID NCT07077161

Recruiting now Disease control Sponsor: dr. Tom van der Hulle Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking cabozantinib in a pattern that skips some days can keep the same drug levels in the body as the standard daily dose. It involves 34 adults with advanced kidney cancer who are already on a stable dose. Participants will try both the standard and the experimental regimen for four weeks each to compare drug exposure, side effects, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabozantinib
What this could lead to: If successful, this could offer a cheaper, equally effective way to take cabozantinib for kidney cancer patients.
What could go wrong: This is a small, early-phase trial with only 34 participants. The experimental dosing may not work as well or could cause different side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

LUMC
RECRUITING

Leiden, South Holland, 2333ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.